CLASSIFICATION
Steroid antibacterials
ACNE
No
WATER RETENTION
No
HBR
No
HEPATOTOXICITY
No
AROMATIZATION
No
MANUFACTURER
Abdi Ibrahim
WAREHOUSE
International Warehouse 2
ACTIVE INGREDIENT
Sodium fusidate
What is Fucidin?
Fucidin is a powerful antibiotic specifically designed to combat a variety of staphylococcal infections caused by susceptible bacteria. This effective treatment addresses conditions such as skin infections, osteomyelitis, pneumonia, sepsis, wound infections, endocarditis, and superinfected cystic fibrosis.
When oral administration isn't feasible, particularly in cases of unreliable gastrointestinal absorption, Fucidin is administered intravenously for optimal effectiveness.
Dosage and Administration
Dosage
For staphylococcal skin infections:
Adults: - Standard dosage: 250 mg of sodium fusidate, taken twice daily for a duration of 5 to 10 days.
For more severe staphylococcal infections including osteomyelitis, pneumonia, sepsis, wound infections, endocarditis, and superinfected cystic fibrosis:
Adults: - Standard dosage: 500 mg of sodium fusidate, administered three times daily.
In critical cases with aggressive infections, dosages can be increased or combined with additional therapies as deemed appropriate.
No adjustments are typically needed for elderly patients or those with renal impairment, as Fucidin is primarily cleared through bile. Additionally, patients undergoing hemodialysis do not require dosage modifications, given that Fucidin is not significantly removed during the process.
Administration Method
Fucidin is intended for oral use.
Special Warnings and Precautions
It's essential to avoid using statins (HMG-CoA reductase inhibitors) alongside systemic Fucidin due to reported cases of rhabdomyolysis, including fatalities. If systemic Fucidin is necessary, statin therapy should be paused until treatment concludes. Patients should seek immediate medical care if they experience muscle weakness, pain, or tenderness, and can resume statin therapy seven days after the last dose of systemic Fucidin. In rare instances requiring extended use of systemic Fucidin for severe infections, the concurrent use of statins should be carefully assessed and managed.
There have been isolated reports of severe skin reactions, including Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome, toxic epidermal necrolysis (Lyell's syndrome), and Stevens-Johnson syndrome associated with systemic Fucidin. Patients must remain vigilant for skin reactions and symptoms of these serious conditions, which may manifest within the first weeks of treatment. If such reactions are suspected, Fucidin should be discontinued immediately and not reintroduced.
Fusidic acid is metabolized by the liver and excreted through bile. Instances of elevated liver enzymes and jaundice have been reported during systemic Fucidin therapy, although these effects are typically reversible upon discontinuation of the medication.
Systemic Fucidin should be used cautiously in individuals with liver dysfunction or those on potentially hepatotoxic medications; regular monitoring of liver function is recommended. Care is also advised for patients with biliary disease or obstruction, as well as those on HIV protease inhibitors. Fusidic acid may inhibit bilirubin's binding to albumin, necessitating caution when given to patients with impaired bilirubin transport, particularly in neonates, due to the risk of kernicterus.
Reports of bacterial resistance linked to fusidic acid usage have surfaced. As with all antibiotics, prolonged or repeated use may increase the risk of resistance development.
Patients with rare hereditary conditions such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption should avoid this medication due to its lactose content.